CHPG

• UNSPSC Description:

  CHPG is a selective mGluR5 agonist, and attenuates SO2-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells[1]. CHPG protects against traumatic brain injury (TBI) in vitro and in vivo by activation of the ERK and Akt signaling pathways[2].

• Target Antigen:

  Akt; ERK; mGluR; NF-κB

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;MAPK/ERK Pathway;Neuronal Signaling;NF-κB;PI3K/Akt/mTOR;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/chpg.html

• Purity:

  99.0

• Solubility:

  1M NaOH : 25 mg/mL (ultrasonic;adjust pH to 11 with NaOH)|DMSO : < 1 mg/mL (ultrasonic)

• Smiles:

  O=C(O)C(N)C1=CC(O)=CC=C1Cl

• Molecular Weight:

  201.609

• References & Citations:

  [1]Qiu JL, et al. The selective mGluR5 agonist CHPG attenuates SO₂-induced oxidative stress and inflammation through TSG-6/NF-κB pathway in BV2 microglial cells. Neurochem Int. 2015 Jun-Jul;85-86:46-52.|[2]Chen T, et al. The selective mGluR5 agonist CHPG protects against traumatic brain injury in vitro and in vivo via ERK and Akt pathway. Int J Mol Med. 2012 Apr;29(4):630-6.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  170846-74-9